Abstract
Coronary heart disease is the most common cause of death among diabetic patients. The increased risk of coronary heart disease in type 2 diabetes is due, in part, to lipid abnormalities often present in the diabetic patient. Diabetic dyslipidemia is characterized by elevated triglycerides, low high‐density lipoprotein cholesterol (HDL‐C) and an increased preponderance of small, dense low‐density lipoprotein cholesterol (LDL‐C) particles. Current guidelines for the prevention of coronary heart disease in diabetic patients identify elevated LDL‐C as the primary target of lipid‐lowering therapy, and recommend statins as the first‐line treatment for diabetic dyslipidemia. This review evaluates the large statin trials that have included diabetic patients, and discusses the role of combination therapy in managing dyslipidemia in diabetic patients. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: lipids, statins, diabetes mellitus, cardiovascular disease
Full Text
The Full Text of this article is available as a PDF (113.3 KB).
References
- 1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American heart association and the American diabetes association. Diabetes Care 2007; 30: 162–172. [DOI] [PubMed] [Google Scholar]
- 2. American Diabetes Association Position Statement. Standards of medical care in diabetes‐2007. Diabetes Care 2007; 30(suppl 1): S4–S41. [DOI] [PubMed] [Google Scholar]
- 3. Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, et al.: Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005; 70: 263–269. [DOI] [PubMed] [Google Scholar]
- 4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al.: Implications of recent clinical trials for the National Cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110: 227–239. [DOI] [PubMed] [Google Scholar]
- 5. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363–2372. [DOI] [PubMed] [Google Scholar]
- 6. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–620. [DOI] [PubMed] [Google Scholar]
- 7. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose‐intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513–2519. [DOI] [PubMed] [Google Scholar]
- 8. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, et al.: Secondary prevention of cardiovascular events with long‐term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713–2721. [DOI] [PubMed] [Google Scholar]
- 9. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF heart protection study of cholesterol‐lowering with simvastatin in 5963 people with diabetes: a randomised placebo‐controlled trial. Lancet 2003; 361: 2005–2016. [DOI] [PubMed] [Google Scholar]
- 10. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet 2004; 364: 685–696. [DOI] [PubMed] [Google Scholar]
- 11. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002; 288: 2998–3007. [DOI] [PubMed] [Google Scholar]
- 12. Knopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non‐insulin‐dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478–1485. [DOI] [PubMed] [Google Scholar]
- 13. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo‐Scandinavian Cardiac Outcomes Trial‐lipid‐lowering arm (ASCOT‐LLA). Diabetes Care 2005; 28: 1151–1157. [DOI] [PubMed] [Google Scholar]
- 14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435. [DOI] [PubMed] [Google Scholar]
- 15. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–1226. [DOI] [PubMed] [Google Scholar]
- 16. Ahmed S, Cannon CP, Murphy SA, Braunwald E: Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT‐TIMI 22 trial. Eur Heart J 2006; 27: 2323–2329. [DOI] [PubMed] [Google Scholar]
- 17. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al.: Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278. [DOI] [PubMed] [Google Scholar]
- 18. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non‐diabetic patients: meta‐analysis of randomised controlled trials. BMJ 2006; 332: 1115–1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, et al.: Reduced coronary events in simvastatin‐treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661–2667. [DOI] [PubMed] [Google Scholar]
- 20. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820–825. [DOI] [PubMed] [Google Scholar]
- 21. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high‐density lipoprotein intervention trial (VA‐HIT). Arch Intern Med 2002; 162: 2597–2604. [DOI] [PubMed] [Google Scholar]
- 22. Keech A, Simes RJ, Barter P, Best J, Scott R, et al.: Effects of long‐term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861. [DOI] [PubMed] [Google Scholar]
- 23. Karalis D, Ishisaka D, Luo D: Effects of increased dosages of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 2007; 100: 445–449. [DOI] [PubMed] [Google Scholar]
- 24. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, et al.: High‐density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15. [DOI] [PubMed] [Google Scholar]
- 25. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, et al.: Statin therapy, LDL cholesterol, C‐reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29–38. [DOI] [PubMed] [Google Scholar]
- 26. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C: Strong decrease of high sensitivity C‐reactive protein with high‐dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129–135. [DOI] [PubMed] [Google Scholar]
- 27. Gavish D, Leibovitz E, Shapira I, Rubinstein A: Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000; 247: 563–569. [DOI] [PubMed] [Google Scholar]
- 28. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198–1202. [DOI] [PubMed] [Google Scholar]
- 29. Davidson MH: Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005; 96: 3K–13K; discussion 34K–35K. [DOI] [PubMed] [Google Scholar]
- 30. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–1592. [DOI] [PubMed] [Google Scholar]
- 31. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended‐release niacin on carotid intima‐ media thickness: ARBITER 3. Curr Med Res Opin 2006; 22: 2243–2250. [DOI] [PubMed] [Google Scholar]
- 32. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double‐blind trial. Circulation 2003; 107: 2409–2415. [DOI] [PubMed] [Google Scholar]